Positron, a molecular imaging medical device company, has signed an exclusive agreement to sell and distribute the NeuSight PET-CT 64 slice scanner in North America.

The agreement with Shenyang Intelligent Neuclear Medical Technology, a subsidiary of Neusoft Medical Systems, positions Positron to introduce the scanner to the nuclear cardiac imaging market next month.

Approved by the US Food and Drug Administration (FDA), the NeuSight PET-CT 64 slice scanner offers high performance and has been installed worldwide.

Designed for clinical exploration and data acquisition, the scanner features advanced identification technology for improved scanning speed and precision.

Positron president Adel Abdullah said: “The NeuSight PET-CT has been extremely successful for Neusoft Medical Systems with approximately 500 systems sold internationally, and we are confident for the NeuSight system to have similar success in the US, the largest imaging devices market, as well as Canada and Mexico.

“NeuSight PET-CT is an ideal versatile scanner suitable for SPECT providers adopting the PET modality, as well as oncology practices seeking new systems for enhanced diagnostic and disease management capabilities.

“Positron’s PET-CT and services are the best value of technology and practice sustainability in the industry, and we believe our new system offers the perfect balance of quality, speed, size, and low cost to own and operate for any nuclear medicine provider seeking the best in PET imaging.”

The NeuSight PET-CT system offers anatomic and functional imaging with qualified designs and technology. It is versatile, catering to multiple molecular imaging applications including heart, tumour, and brain studies.

Last year, Positron and Ochsner Clinic Foundation planned to commence a clinical study of the Affinity PET-CT imaging device.